2017 ACVIM Forum Research Abstract Program

No cats vomited during the study, 2 of 10 cats in the 15 mg/kg TID group were hyporexic, but they recovered at discontinuation of MMF. A mild reduction in serum protein levels, PCV, and platelet counts occurred between day 1 and day 7 of the study. No other values were altered by MMF use in the cats. This study describes the clinical parameters and PK of oral MMF administration in healthy cats. Future studies will evaluate the pharmacodynamics of MPA in patients receiving these doses of MMF. The purpose of this study is to use a limited sampling strategy to determine if pharmacokinetics of oral mirtazapine is altered in cats with liver disease compared to healthy age matched control cats (AMC). Twenty cats were enrolled; 10 with liver disease and 10 apparently healthy age-matched controls. Cats with liver disease did not have evidence of chronic kidney disease or hyperthyroidism based on complete blood count, serum biochemistry, urinalysis and total T4 as well as no recent exposure to mirtazapine. Apparently healthy AMC cats were screened with a physical examination, complete blood count, serum biochemistry, urinalysis and total T4. Blood was drawn from all cats 1 hour and 4 hours following one 1.87 mg oral dose of mirtazapine. In a subset of 6 cats from each group, blood was also obtained 24 hours post-administration. Mirtazapine concentrations were measured by liquid chromatography coupled to tandem mass spectrometry. Drug exposure (AUC) and half-life was predicted using a limited sampling approach based on multiple linear regression analysis from previous full sampling studies, and estimated using non-compartmental methods. The data was not normally distributed and a Mann Whitney test was used to compare parameters between the two groups and Spearman Rank was used to analyze correlation between liver values and pharmacokinetic parameters.